Nationwide Coverage: Anovo Geographic Reach and Service Consistency
True nationwide specialty pharmacy coverage requires comprehensive infrastructure, robust logistics partnerships, and operational systems designed to overcome geographic challenges. At…
Business Continuity Planning: Anovo’s Redundancy and Disaster Recovery
When patients depend on life-changing rare disease therapies, service interruptions can have devastating health consequences. At Anovo, our business continuity…
September 8, 2025
Behind the Delivery: How Anovo’s 3PL/Wholesale Team Keeps Rare Therapies Moving
At Anovo, every team plays a role in delivering hope to patients living with rare diseases. While many think of…
August 20, 2025
Exclusive Partnership vs Multi-Vendor Models: Anovo’s Economic Advantage
The choice between exclusive partnership and multi-vendor approaches fundamentally shapes program economics, operational efficiency, and patient outcomes. At Anovo, our…
August 13, 2025
Specialty Pharmacy Quality Management: Anovo’s Comprehensive Approach
At Anovo, quality management extends far beyond basic accreditation requirements. Our quality systems are specifically designed for the unique challenges…
July 20, 2025
Why Exclusivity Matters: Redefining Patient-Centricity in Rare and Ultra-Rare Drug Commercialization
In the rare disease space, every patient story is deeply personal, and every barrier to access feels monumental. From navigating…
May 27, 2025
The Heart of Our Success: How Our HR Team Fuels Growth & CultureInvesting in Training to Elevate Patient Care
At Anovo, we know that our success starts with our people. Behind every dedicated team member, every seamless patient experience,…
April 30, 2025
Preparing for Cell and Gene Therapy Logistics: Anovo’s Infrastructure Development
As cell and gene therapies move from clinical trials toward commercial markets, Anovo is strategically preparing the infrastructure to support…
April 12, 2025
Investing in Training to Elevate Patient Care
At Anovo, we believe that exceptional patient support starts with a well-trained, knowledgeable team. As we continue to grow, we’ve…
April 3, 2025
Case Study: Transitioning Egetis Therapeutics’ Expanded Access Program to Anovo
As Egetis prepared for its first launch, it made the strategic decision to partner for the management of its Expanded…
March 13, 2025
How Anovo Builds Dedicated Teams to Support Your Rare Disease Therapy
At Anovo, we understand that complex rare disease therapies require high-touch service that large payer- and Pharmacy Benefit Manager-owned Specialty…
January 24, 2025
Justin’s Story: Living with Duchenne Muscular Dystrophy
When Justin was first diagnosed with Duchenne muscular dystrophy, his parents, Amanda and Andrew, weren’t sure how to navigate the…
January 23, 2025
Eton Pharmaceuticals & Anovo Partner to Expand Access for Patients with Severe Primary Insulin-Like Growth Factor 1 Deficiency
Eton Pharmaceuticals is dedicated to developing and commercializing treatments for rare diseases, with a strong focus on pediatric endocrinology. Their…
December 20, 2024
Jaette’s Story: Living with Rett Syndrome
Siri’s mom, Jaette, has been navigating the challenges of Rett syndrome since her daughter’s diagnosis at four years old. In…
November 4, 2024
Supporting Innovative ALS Treatments with Clene Nanomedicine & Synapticure
Anovo is proud to announce a new partnership with Clene Nanomedicine, Inc. and Synapticure Inc., supporting their efforts to bring…
October 14, 2024
Advancing Rare Disease Care: Insights from the World Orphan Drug Congress and AAN Annual Meeting
The World Orphan Drug Congress (WODC) and the American Academy of Neurology (AAN) Annual Meeting are where healthcare leaders, advocates,…
June 11, 2024
Jill’s Story: Advocating for Patients with Acromegaly
Jill Sisco isn’t just an advocate – she’s also a patient herself. She’s been living with Acromegaly, a rare disease…
March 6, 2024
Celebrating Five Consecutive Years as a Top Workplace at Anovo
We are thrilled to announce that Anovo has been recognized as a top workplace by The Commercial Appeal for the…
February 6, 2024
FDA Releases Final Guidance on Rare Disease Drug Development
The FDA recently released its final guidance on rare disease drug development, which will have several significant implications for orphan…
January 4, 2024
Egetis Therapeutics & Anovo Unite for MCT8 Patients
Egetis Therapeutics is an innovative pharmaceutical company, focusing on projects in late-stage development for commercialization for treatments of serious diseases…
January 2, 2024
Braynelle’s Story: Living with Dravet Syndrome
Braynelle and Brandon have been managing their son Kai’s diagnosis of Dravet Syndrome since he was four months old. After…
December 3, 2023
Scott’s Story: Living with Lambert-Eaton Myasthenic Syndrome
Experience Scott’s extraordinary journey living with Lambert-Eaton myasthenic syndrome (LEMS), where for over a decade, he’s been his own advocate,…
November 15, 2023
Kevin’s Story: Living with Lambert-Eaton Myasthenic Syndrome
Meet Kevin, an Anovo patient living with Lambert-Eaton myasthenic syndrome. Despite the challenges he’s faced in not always being able…
November 1, 2023
Acadia and Anovo Partner to Transform Rett Syndrome Care
Acadia Pharmaceuticals, Inc. is a pioneering biopharmaceutical company dedicated to transforming the treatment landscape for central nervous system (CNS) disorders….
October 3, 2023
Anovo Recognized for Creation of “End-to-End” Service Model that Benefits Both Patients and Manufacturers
Anovo is excited to announce that we have been featured in an article for USA Today, which details our unique…
September 5, 2023